Mary Bird Perkins Cancer Center
Latest Content
Please check back later for more content.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Selinexor Plus Ruxolitinib Improves Spleen Responses, Shows OS Signal in Frontline Myelofibrosis
2
ASCO 2026 Breast Cancer Highlights: Beyond the LBAs
3
Phase 3 Trial of Sacituzumab Govitecan Plus Pembrolizumab Stopped Early in First-Line mNSCLC
4
ASCO 2026: ADCs, KRAS Inhibitors & the Future of Breast Cancer Treatment with Dr Tarantino
5